Advertisement


Andrew D. Zelenetz, MD, PhD, and Stephan Stilgenbauer, MD, PhD on CLL and Venetoclax: Clinical Trial Results

2015 ASH Annual Meeting

Advertisement

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Stephan Stilgenbauer, MD, PhD, of the University of Ulm, discuss this late-breaking abstract on venetoclax monotherapy and deep remissions in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p deletion (Abstract LBA6).



Related Videos

Lymphoma

Olivier Casasnovas, MD, on Advanced-Stage Hodgkin Lymphoma: Interim Analysis of the Lysa Study

Olivier Casasnovas, MD, of Hôpital Le Bocage, discusses a phase III study comparing an early PET-driven treatment de-escalation to a not PET-monitored strategy in patients with adv...

Multiple Myeloma

James N. Kochenderfer, MD, on Multiple Myeloma: Results of a First-in-Humans Clinical Trial

James N. Kochenderfer, MD, of the National Cancer Institute, reports on remissions of multiple myeloma during a trial of T cells expressing an anti-B-cell maturation antigen chimer...

Lymphoma

Nathan Hale Fowler, MD, on Follicular Lymphoma: Ibrutinib Plus Rituximab Study Results

Nathan Hale Fowler, MD, of MD Anderson Cancer Center, discusses a multicenter trial in which ibrutinib plus rituximab was administered to treatment-naive patients with follicular l...

Lymphoma

Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD, on Venetoclax for NHL

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and John F. Gerecitano, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss a phase I st...

Leukemia

Julie Vose, MD, MBA, on ALL Overall Survival: Academic vs Nonacademic Hospitals

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses a retrospective analysis of data on the overall survival of patients with acute lymphoblastic leukemia ...

Advertisement

Advertisement



Advertisement